Argenx Se (ARGX) Research & Development (2016 - 2026)
Argenx Se's (ARGX) quarterly Research & Development came in at $1.4 billion in Q2 2026, up 518.68% YoY from $221.8 million in Q2 2025, and up 409.71% on a QoQ basis from -$443.0 million in Q1 2026.
Argenx Se (ARGX) Research & Development (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Research & Development data on file, last reported at $1.4 billion in Q2 2026.
- Quarterly Research & Development rose 518.68% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $201.6 million (up 117.21% YoY) and the FY2025 annual result came in at $1.4 billion, up 38.71% from the prior year.
- Research & Development grew to $1.4 billion in Q2 2026, from -$443.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.4 billion in Q2 2026 to a low of -$443.0 million in Q1 2026.
- A 5-year average of -$163.5 million and a median of -$230.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development sank 107.29% — and 2026, when it surged 518.68%.
- Tracing ARGX's Research & Development over 5 years: stood at -$147.8 million in 2022, then slumped by 107.29% to -$306.4 million in 2023, then advanced by 2.98% to -$297.2 million in 2024, then decreased by 25.06% to -$371.7 million in 2025, then surged by 469.1% to $1.4 billion in 2026.
- The last three Research & Development figures came in at $1.4 billion (Q2 2026), -$443.0 million (Q1 2026), and -$371.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 202.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.37 Bn |
| Mar 31, 2026 | -443.00 Mn |
| Dec 31, 2025 | -371.71 Mn |
| Sep 30, 2025 | -355.65 Mn |
| Jun 30, 2025 | -327.70 Mn |
| Mar 31, 2025 | -311.00 Mn |
| Dec 31, 2024 | -297.23 Mn |
| Sep 30, 2024 | -235.94 Mn |
| Jun 30, 2024 | -225.29 Mn |
| Mar 31, 2024 | -224.97 Mn |
| Dec 31, 2023 | -306.37 Mn |
| Sep 30, 2023 | -191.76 Mn |
| Jun 30, 2023 | -195.51 Mn |
| Mar 31, 2023 | -165.86 Mn |
| Dec 31, 2022 | -147.80 Mn |
| Sep 30, 2022 | -236.68 Mn |
| Jun 30, 2022 | -126.92 Mn |
| Mar 31, 2022 | -151.97 Mn |
| Dec 31, 2021 | -167.17 Mn |
| Sep 30, 2021 | -139.44 Mn |